{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:35Z","timestamp":1792097315634,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13300-023-01523-0","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:01:48Z","timestamp":1704430908000},"page":"521-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Effect of Sodium\u2013Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type\u00a01 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","volume":"11","author":"HJ Heerspink","year":"2023","unstructured":"Heerspink HJ, Cherney DZ, Groop P-H, et al. People with type\u00a01 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 2023;11:536\u201340. https:\/\/doi.org\/10.1016\/S2213-8587(23)00168-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1523_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"P-H Groop","year":"2009","unstructured":"Groop P-H, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type\u00a01 diabetes. Diabetes. 2009;58:1651\u20138. https:\/\/doi.org\/10.2337\/db08-1543.","journal-title":"Diabetes"},{"key":"1523_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2213-8587(22)00099-7","volume":"10","author":"F Jansson Sigfrids","year":"2022","unstructured":"Jansson Sigfrids F, Groop P-H, Harjutsalo V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type\u00a01 diabetes aged 0\u201314\u00a0years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol. 2022;10:489\u201398. https:\/\/doi.org\/10.1016\/S2213-8587(22)00099-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1523_CR4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson J, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet"},{"key":"1523_CR5","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Training. https:\/\/training.cochrane.org\/handbook\/current. Accessed Jan 17, 2023."},{"key":"1523_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/BMJ.N71","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https:\/\/doi.org\/10.1136\/BMJ.N71.","journal-title":"BMJ"},{"key":"1523_CR7","doi-asserted-by":"publisher","unstructured":"Haddaway NR, Grainger MJ, Gray CT. citationchaser: an R package and Shiny app for forward and backward citations chasing in academic searching; 2021. https:\/\/doi.org\/10.5281\/ZENODO.4543513.","DOI":"10.5281\/ZENODO.4543513"},{"key":"1523_CR8","doi-asserted-by":"publisher","unstructured":"Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: Abstrackr. IHI\u201912\u2014Proc 2nd ACM SIGHIT Int Heal Informatics Symp. 2012:819\u201323. https:\/\/doi.org\/10.1145\/2110363.2110464.","DOI":"10.1145\/2110363.2110464"},{"key":"1523_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/BMJ.L4898.","journal-title":"BMJ"},{"key":"1523_CR10","unstructured":"GRADEpro. https:\/\/www.gradepro.org\/. Accessed March 1, 2023."},{"key":"1523_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41591-022-01805-3","volume":"28","author":"A Haidar","year":"2022","unstructured":"Haidar A, Lovblom LE, Cardinez N, et al. Empagliflozin add-on therapy to closed-loop insulin delivery in type\u00a01 diabetes: a 2 \u00d7 2 factorial randomized crossover trial. Nat Med. 2022;28:1269\u201376. https:\/\/doi.org\/10.1038\/s41591-022-01805-3.","journal-title":"Nat Med"},{"key":"1523_CR12","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Bjornstad P, Perkins BA, et al. Kidney effects of empagliflozin in people with type\u00a01 diabetes. Clin J Am Soc Nephrol. 2021;16:1715\u20139. https:\/\/doi.org\/10.2215\/CJN.07700621.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1523_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/dia.2020.0079","volume":"23","author":"BW Bode","year":"2021","unstructured":"Bode BW, Cengiz E, Wadwa RP, et al. Effects of sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type\u00a01 diabetes: the JDRF sotagliflozin study. Diabetes Technol Ther. 2021;23:59\u201369. https:\/\/doi.org\/10.1089\/dia.2020.0079.","journal-title":"Diabetes Technol Ther"},{"key":"1523_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","volume":"8","author":"P-H Groop","year":"2020","unstructured":"Groop P-H, Dandona P, Phillip M, et al. Effect of dapagliflozin as an adjunct to insulin over 52\u00a0weeks in individuals with type\u00a01 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:845\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(20)30280-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1523_CR15","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2337\/dc19-0937","volume":"42","author":"DH van Raalte","year":"2019","unstructured":"van Raalte DH, Bjornstad P, Persson F, et al. The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type\u00a01 diabetes. Diabetes Care. 2019;42:1921\u20139. https:\/\/doi.org\/10.2337\/dc19-0937.","journal-title":"Diabetes Care"},{"key":"1523_CR16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/dom.13807","volume":"21","author":"K Kaku","year":"2019","unstructured":"Kaku K, Isaka H, Sakatani T, Toyoshima J. Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type\u00a01 diabetes mellitus: a randomized, double-blind, phase\u00a03 trial. Diabetes Obes Metab. 2019;21:2284\u201393. https:\/\/doi.org\/10.1111\/dom.13807.","journal-title":"Diabetes Obes Metab"},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type\u00a01 diabetes. N Engl J Med. 2017;377:2337\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1708337.","journal-title":"N Engl J Med"},{"key":"1523_CR18","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1210\/jc.2016-1451","volume":"101","author":"ND Kuhadiya","year":"2016","unstructured":"Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type\u00a01 diabetes. J Clin Endocrinol Metab. 2016;101:3506\u201315. https:\/\/doi.org\/10.1210\/jc.2016-1451.","journal-title":"J Clin Endocrinol Metab"},{"key":"1523_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"Pollock C, Stef\u00e1nsson B, Reyner D, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type\u00a02 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, pla. Lancet Diabetes Endocrinol. 2019;7:429\u201341. https:\/\/doi.org\/10.1016\/S2213-8587(19)30086-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1523_CR20","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type\u00a02 diabetes and moderate renal impairment (chronic kidney disease stage\u00a03A): the DERIVE Study. Diabetes Obes Metab. 2018;20:2532\u201340. https:\/\/doi.org\/10.1111\/dom.13413.","journal-title":"Diabetes Obes Metab"},{"key":"1523_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"J-F Yale","year":"2013","unstructured":"Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type\u00a02 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463\u201373. https:\/\/doi.org\/10.1111\/dom.12090.","journal-title":"Diabetes Obes Metab"},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/1753-0407.12890","volume":"11","author":"K Li","year":"2019","unstructured":"Li K, Xu G. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type\u00a01 diabetes: a meta-analysis of randomized controlled trials. J Diabetes. 2019;11:645\u201355. https:\/\/doi.org\/10.1111\/1753-0407.12890.","journal-title":"J Diabetes"},{"key":"1523_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5603\/EP.a2020.0034","volume":"71","author":"Y Huang","year":"2020","unstructured":"Huang Y, Jiang Z, Wei Y. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type\u00a01 diabetes: systematic review and meta-analysis. Endokrynol Pol. 2020;71:325\u201333. https:\/\/doi.org\/10.5603\/EP.a2020.0034.","journal-title":"Endokrynol Pol"},{"key":"1523_CR24","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type\u00a01 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023;66:1869\u201381. https:\/\/doi.org\/10.1007\/s00125-023-05975-8.","journal-title":"Diabetologia"},{"key":"1523_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110794","volume":"202","author":"J Hironaka","year":"2023","unstructured":"Hironaka J, Okada H, Hamaguchi M, et al. Effects of dapagliflozin on renal function in type\u00a01 diabetes patients in the real world: a retrospective multicenter study of the KAMOGAWA-A cohort. Diabetes Res Clin Pract. 2023;202: 110794. https:\/\/doi.org\/10.1016\/j.diabres.2023.110794.","journal-title":"Diabetes Res Clin Pract"},{"key":"1523_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2023.10.010","author":"J Nan","year":"2023","unstructured":"Nan J, Wang D, Zhong R, et al. Sodium glucose cotransporter2 inhibitors for type\u00a01 diabetes mellitus: a meta-analysis of randomized controlled trials. Prim Care Diabetes. 2023. https:\/\/doi.org\/10.1016\/j.pcd.2023.10.010.","journal-title":"Prim Care Diabetes"},{"key":"1523_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003461","volume":"17","author":"G Musso","year":"2020","unstructured":"Musso G, Sircana A, Saba F, Cassader M, Gambino R. Assessing the risk of ketoacidosis due to sodium\u2013glucose cotransporter (SGLT)-2 inhibitors in patients with type\u00a01 diabetes: a meta-analysis and meta-regression. PLoS Med. 2020;17:e1003461. https:\/\/doi.org\/10.1371\/journal.pmed.1003461.","journal-title":"PLoS Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-023-01523-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T05:27:51Z","timestamp":1707024471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-023-01523-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s13300-023-01523-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Djordje S. Popovic declares associations with Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and W\u00f6rwag Pharma. Theocharis Koufakis has received honoraria for lectures from AstraZeneca, Boehringer-Ingelheim, Pharmaserve Lilly, and Novo Nordisk, for advisory boards from Novo Nordisk and Boehringer-Ingelheim, and has participated in sponsored studies by Eli Lilly and Novo Nordisk. Nikolaos Papanas has been an advisory board member of AstraZeneca, Boehringer-Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Elpen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. Manfredi Rizzo is Editorial Board Member of Diabetes Therapy and has given lectures, received honoraria and research support, and participated in conferences, advisory boards, and clinical trials sponsored by many pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi, and Servier. None of the aforementioned pharmaceutical companies had any role in this article, which has been written independently, without any financial or professional help, and reflects only the opinion of the authors, without any role of the industry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study adhered to the principles of the Cochrane Handbook for systematic reviews [] and the reporting conformed to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) 2020 guidelines []. The protocol was prospectively registered on the Open Science Framework () and was adhered to without deviations. As this is a meta-analysis of published RCTs, no ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}